Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity

Pharmacogenomics Reporter took stock of industry expectations ahead of FDA's upcoming meeting to discuss the agency's strategy for regulating laboratory-developed tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.